Piper Sandler Reiterates Overweight on Axsome Therapeutics, Maintains $258 Price Target

Benzinga · 2d ago
Piper Sandler analyst David Amsellem reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and maintains $258 price target.